BARR WINS PATENT SUIT ON NOLVADEX
BARR WINS PATENT SUIT ON NOLVADEX POMONA, N.Y., April 27 /PRNewswire/ -- Barr Laboratories, Inc.
(AMEX: BRL) has won a court challenge to ICI Pharmaceutical's patent on tamoxifen citrate, brand named Nolvadex (R). The Federal Court in Southern District of New York today ruled in favor of the 1987 challenge.
The court last heard arguments in 1990. The ruling removes one of the last impediments to Barr bringing a generic version of tamoxifen citrate to market. Barr has held an approved ANDA for tamoxifen citrate from the Food and Drug Administration since April 1987. There is no other FDA-approved generic version of tamoxifen citrate on the market. Barr estimates it will be able to bring the product to market in less than a year. "This case demonstrates why America needs the generic drug industry. We can successfully challenge patents that shouldn't have been given in the first place," said Barr's president Edwin A. Cohen. "This win will help millions of women fight breast cancer with a much lower-cost alternative than the monopolistic prices of ICI." Tamoxifen citrate is an anti-neoplastic, used to prevent the recurrence of breast cancer following treatment by mastectomy or radiation. ICI's domestic annual sales of Nolvadex(R) are approximately $200 million. Barr Laboratories is a manufacturer of generic pharmaceuticals. -0- 4/27/92 /CONTACT: Edwin A. Cohen of Barr Laboratories, 914-362-1100/ (BRL) CO: Barr Laboratories Inc.; ICI Pharmaceuticals ST: New York, Delaware IN: MTC SU:
AH-OS -- NY045 -- 3061 04/27/92 11:02 EDT
|Printer friendly Cite/link Email Feedback|
|Date:||Apr 27, 1992|
|Previous Article:||MOBIL TO START UP NEW PHOSPHATE MINE IN FLORIDA|
|Next Article:||WEYERHAEUSER CELEBRATES 25TH ANNIVERSARY OF HIGH YIELD FORESTRY MANAGEMENT PROGRAM, MIMA DOUGLAS FIR TREE NURSERY|